These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

873 related articles for article (PubMed ID: 25890386)

  • 1. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
    Eschner AK; Mugnai K
    Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
    Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
    BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demonstration of the ability of a canine Lyme vaccine to reduce the incidence of histological synovial lesions following experimentally-induced canine Lyme borreliosis.
    Grosenbaugh DA; Rissi DR; Krimer PM
    Vet Immunol Immunopathol; 2016 Nov; 180():29-33. PubMed ID: 27692092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fluorescent bead-based multiplex assay for the simultaneous detection of antibodies to B. burgdorferi outer surface proteins in canine serum.
    Wagner B; Freer H; Rollins A; Erb HN
    Vet Immunol Immunopathol; 2011 Apr; 140(3-4):190-8. PubMed ID: 21208663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against tick-transmitted Lyme disease in dogs vaccinated with a multiantigenic vaccine.
    Straubinger RK; Dharma Rao T; Davidson E; Summers BA; Jacobson RH; Frey AB
    Vaccine; 2001 Oct; 20(1-2):181-93. PubMed ID: 11567763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a nonadjuvanted, outer surface protein A, recombinant vaccine in dogs after challenge by ticks naturally infected with Borrelia burgdorferi.
    Conlon JA; Mather TN; Tanner P; Gallo G; Jacobson RH
    Vet Ther; 2000; 1(2):96-107. PubMed ID: 19757556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with the ospA- and ospB-Negative Borrelia burgdorferi Strain 50772 Provides Significant Protection against Canine Lyme Disease.
    LaFleur RL; Callister SM; Dant JC; Wasmoen TL; Jobe DA; Lovrich SD
    Clin Vaccine Immunol; 2015 Jul; 22(7):836-9. PubMed ID: 25972405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.
    Scheckelhoff MR; Telford SR; Hu LT
    Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease.
    LaFleur RL; Dant JC; Wasmoen TL; Callister SM; Jobe DA; Lovrich SD; Warner TF; Abdelmagid O; Schell RF
    Clin Vaccine Immunol; 2009 Feb; 16(2):253-9. PubMed ID: 19052162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OspA immunization decreases transmission of Borrelia burgdorferi spirochetes from infected Peromyscus leucopus mice to larval Ixodes scapularis ticks.
    Tsao J; Barbour AG; Luke CJ; Fikrig E; Fish D
    Vector Borne Zoonotic Dis; 2001; 1(1):65-74. PubMed ID: 12653137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and optimization of a novel vaccine for protection against Lyme borreliosis.
    Comstedt P; Hanner M; Schüler W; Meinke A; Schlegl R; Lundberg U
    Vaccine; 2015 Nov; 33(44):5982-8. PubMed ID: 26277070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of antibody responses to outer surface protein (Osp)A and OspC in dogs vaccinated with Lyme disease vaccines.
    Camire AC; Hatke AL; King VL; Millership J; Ritter DM; Sobell N; Weber A; Marconi RT
    Vet J; 2021 Jul; 273():105676. PubMed ID: 34148599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroprevalence of Borrelia burgdorferi-specific C6 antibody in dogs before and after implementation of a nonadjuvanted recombinant outer surface protein A vaccine in a Rhode Island small animal clinic.
    Hebert D; Eschner A
    Vet Ther; 2010; 11(3):E1-9. PubMed ID: 20960414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dogs vaccinated with common Lyme disease vaccines do not respond to IR6, the conserved immunodominant region of the VlsE surface protein of Borrelia burgdorferi.
    O'Connor TP; Esty KJ; Hanscom JL; Shields P; Philipp MT
    Clin Diagn Lab Immunol; 2004 May; 11(3):458-62. PubMed ID: 15138170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model.
    Schwendinger MG; O'Rourke M; Traweger A; Savidis-Dacho H; Pilz A; Portsmouth D; Livey I; Barrett PN; Crowe BA
    PLoS One; 2013; 8(11):e79022. PubMed ID: 24260146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Borrelia burgdorferi ospC genotypes in canine tissue following tick infestation: implications for Lyme disease vaccine and diagnostic assay design.
    Rhodes DV; Earnhart CG; Mather TN; Meeus PF; Marconi RT
    Vet J; 2013 Nov; 198(2):412-8. PubMed ID: 23962611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.
    Wressnigg N; Barrett PN; Pöllabauer EM; O'Rourke M; Portsmouth D; Schwendinger MG; Crowe BA; Livey I; Dvorak T; Schmitt B; Zeitlinger M; Kollaritsch H; Esen M; Kremsner PG; Jelinek T; Aschoff R; Weisser R; Naudts IF; Aichinger G
    Clin Vaccine Immunol; 2014 Nov; 21(11):1490-9. PubMed ID: 25185574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new approach to a Lyme disease vaccine.
    Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reductions in human Lyme disease risk due to the effects of oral vaccination on tick-to-mouse and mouse-to-tick transmission.
    Voordouw MJ; Tupper H; Önder Ö; Devevey G; Graves CJ; Kemps BD; Brisson D
    Vector Borne Zoonotic Dis; 2013 Apr; 13(4):203-14. PubMed ID: 23428088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis.
    Zhao H; Bao FF; Liu A
    J Infect Dev Ctries; 2017 Jan; 11(1):1-9. PubMed ID: 28141584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.